CEO: Bryan Morton

Advent Contact: Raj Parekh

Specialty pharmaceutical company developing Erwinaze for the treatment of pediatric acute lymphocytic leukemia

EUSA was created in 2006 to build a trans-Atlantic speciality pharma company. EUSA acquired several clinical assets and successfully guided Erwinaze, a first-in-class product for the treatment of certain cancers in children, to approval in the US.

Advent invested in the Series B financing in 2007. EUSA was acquired by Jazz Pharma in 2012 for $700m.